WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.
Category Archives: AZBio News
NuvOx Announces First Patient in Phase IIb Stroke Trial
Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO).
The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between the National Institute for Health Care Research (NIHR) and the Medical Research Council (MRC). The trial is also co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.Continue reading
U of A College of Medicine – Phoenix and Onvida Health announce groundbreaking rural health partnership
The University of Arizona College of Medicine – Phoenix and Onvida Health are partnering to launch Arizona’s first rural regional medical school branch. Deeply rooted in community, the partnership will address the severe physician shortage facing the rural regions of the state.Continue reading
Smarter tools for peering into the microscopic world
Breakthroughs in microbial analysis could enhance disease prediction, environmental protection and our understanding of the planet’s smallest life formsContinue reading
AZBio Celebrates Trailblazers 2025
AZBio and members of the Arizona Business and Bioscience Community came together honor Arizona Legislators and State and Local Elected Officials who have made it possible for the Arizona Bioscience Industry to gain national recognition, build capital infrastructure, and take its place as a leader in both scientific discovery and job growth.Continue reading
Biennial Report on Best Practices in Bioscience Economic Development Initiatives Released
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report on best practices in bioscience economic development initiatives: The U.S. Bioscience Industry: A Powerful Engine for State Economies.Continue reading
C-Path Consortium Adds Gene Editing and Advanced Imaging Leaders to Accelerate Alpha-1 Research
Beam Therapeutics and the Open Source Imaging Consortium join C-Path’s CPA-1 program, bringing gene editing innovation and global lung imaging data resources to advance new therapies for alpha-1 antitrypsin deficiency.Continue reading
C-Path Announces New Name and Strategic Direction for its PRO Consortium
Newly renamed Patient-Centered Evidence Consortium expands focus to advance the science and impact of patient-centered evidence in drug development.Continue reading
Governor Katie Hobbs Appoints Debbie Johnston to Lead Arizona Department of Health Services
News Release November 24, 2025 – Phoenix, AZ – Today, Governor Katie Hobbs announced the appointment of Debbie Johnston to lead the Arizona Department of Health Services. For the past 21 years, she has worked for the Arizona Hospital and Healthcare Association (AzHHA), focusing on policy development and regulatory affairs. During her tenure at AzHHA, Debbie served on various public health boards and committees at the Arizona Department of Health Services, including the State Trauma Advisory Board and the Arizona Health Improvement Plan Steering Committee. Debbie retired earlier this year as Executive Vice President for the Association.Continue reading
C-Path’s International Neonatal Consortium Launches Groundbreaking Neonatal Lab Values GUI Tool to Standardize Reference Ranges in Neonatal Trials
TUCSON, Ariz., November 2025 — Critical Path Institute’s® (C-Path) International Neonatal Consortium (INC) today announced the public launch of its Neonatal Laboratory Values Graphical User Interface (Neo-LV) Tool, a first-of-its-kind platform designed to harmonize and standardize laboratory reference ranges in neonatal research and clinical trials.Continue reading